The decrease in CYP2E1 during the progression of MASLD, as revealed by RNA-seq database analysis, suggests that the level of 19-HETE would decrease while the pro-lipogenic and inflammatory 20-HETE increases. The gene discussed is CYP2E1; the disease is metabolic dysfunction-associated steatotic liver disease.